Premium
Markers of systemic inflammation in children with hyperuricemia
Author(s) -
Wasilewska Anna,
Tenderenda Edyta,
TarantaJanusz Katarzyna,
Tobolczyk Jolanta,
Stypułkowska Justyna
Publication year - 2012
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2011.02582.x
Subject(s) - medicine , hyperuricemia , c reactive protein , body mass index , uric acid , gastroenterology , gout , systemic inflammation , receiver operating characteristic , area under the curve , inflammation , obesity , endocrinology
Aim: The purpose of the study was to investigate serum concentrations of the monocyte chemoattractant protein‐1 (MCP‐1) and high‐sensitivity CRP (hs‐CRP) in children with hyperuricemia and to evaluate its association with obesity. Patients and Methods: The study involved 52 hyperuricemic patients with mean age of 15.53 ± 1.7 years. Twenty‐seven healthy individuals with normal serum uric acid (SUA) level were selected as the control group (C). Serum MCP‐1 and hs‐CRP were measured by enzyme‐linked immunosorbent assay (ELISA) and immunonephelometry, respectively. Results: Hyperuricemic patients showed increased sMCP‐1 (median: 69.58 pg/mL) and hs‐CRP (median: 0.53 mg/L) vs. controls (48.39 pg/mL, 0.24 mg/L; respectively) (p < 0.01). The obese children also presented significantly higher levels of sMCP‐1 and hs‐CRP (median, 81.69 and 1.18 mg/L, respectively) in comparison with nonobese (median, 59.62 and 0.41 mg/L, respectively; p < 0.01). Only hs‐CRP correlated positively with body mass index Z ‐score (r = 0.33, p < 0.05). Receiver operator characteristic analyses checking the sensitivity and specificity of examined markers for hyperuricemia revealed the higher area under the curve (AUC) for sMCP‐1; however, the difference between AUC for sMCP‐1 and for hs‐CRP was not significant (p > 0.05). Conclusion: Serum MCP‐1 and hs‐CRP are elevated in hyperuricemic patients, but the role of obesity in inflammation markers needs further investigation.